Christopher Goetz to Clinical Trials as Topic
This is a "connection" page, showing publications Christopher Goetz has written about Clinical Trials as Topic.
Connection Strength
0.568
-
Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1146-9.
Score: 0.196
-
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol. 2012 Jul; 11(7):643-50.
Score: 0.090
-
Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
Score: 0.074
-
Movement disorders: understanding clinical trials. Lancet Neurol. 2005 Jan; 4(1):5-6.
Score: 0.054
-
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
Score: 0.054
-
Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003 Mar 25; 60(6):917-22.
Score: 0.047
-
Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011 May; 10(5):377-93.
Score: 0.021
-
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
Score: 0.019
-
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
Score: 0.013